SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-11-16
DOI
10.1111/bjh.15677
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia
- (2017) Lili Wang et al. GENOME RESEARCH
- PP32 and SET/TAF-Iβ proteins regulate the acetylation of newly synthesized histone H4
- (2017) Francisco Saavedra et al. NUCLEIC ACIDS RESEARCH
- Chronic lymphocytic leukaemia
- (2017) Thomas J. Kipps et al. Nature Reviews Disease Primers
- The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients
- (2016) Stefano Molica et al. AMERICAN JOURNAL OF HEMATOLOGY
- Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis
- (2016) S. A. Parikh et al. BLOOD
- Targeting PP2A to overcome enzalutamide resistance in AR+ breast tumors
- (2016) Ion Cristóbal et al. ENDOCRINE-RELATED CANCER
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
- (2016) LANCET ONCOLOGY
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Non-coding recurrent mutations in chronic lymphocytic leukaemia
- (2015) Xose S. Puente et al. NATURE
- PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer
- (2015) Paula González-Alonso et al. TUMOR BIOLOGY
- From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies
- (2015) Maria Ciccone et al. Frontiers in Oncology
- Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
- (2014) N. Pflug et al. BLOOD
- SETting OP449 into the PP2A-Activating Drug Family
- (2014) P. Neviani et al. CLINICAL CANCER RESEARCH
- Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
- (2014) I. Cristobal et al. CLINICAL CANCER RESEARCH
- Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
- (2014) A. Agarwal et al. CLINICAL CANCER RESEARCH
- The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy
- (2014) G. Packham et al. HAEMATOLOGICA
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIRC5(survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group
- (2013) Andrew S. Moore et al. PEDIATRIC BLOOD & CANCER
- SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target
- (2011) D. J. Christensen et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia
- (2011) I. Cristobal et al. HAEMATOLOGICA
- Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
- (2011) C H Switzer et al. ONCOGENE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started